National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Partially Closed Meeting
Published Date: 2/2/2026
Notice
Summary
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a meeting on June 2, 2026, that’s partly open to the public and partly closed to protect private info about grant applications. Researchers and the public can join the open session online or in person, while the closed session will review important funding decisions. This meeting helps decide who gets money to study arthritis and related diseases, shaping future research and treatments.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Public Open Session and Videocast
You can attend the open part of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council meeting on June 2, 2026, from 9:30 a.m. to 2:00 p.m. in person at NIH Building 31 (31 Center Drive, Bethesda, MD 20892) or watch the videocast at https://videocast.nih.gov/. Registration is not required for the open portion.
Closed Session to Review Grant Applications
On June 2, 2026, from 2:15 p.m. to 4:30 p.m., the council will meet in closed session to review and evaluate grant applications; discussions may disclose confidential trade secrets, patentable material, or personal information and will be closed to protect that information. This closed review is part of deciding who receives research funding for arthritis and related diseases.
On‑site Security and Visitor ID Procedures
If you come to the NIH campus for the meeting, NIH security procedures require visitors to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and state the purpose of their visit; all visitor vehicles will be inspected before being allowed on campus.
Reasonable Accommodations Available
If you need special assistance to attend the open session (for example, sign language interpretation), you should notify the Contact Person in advance so NIH can provide reasonable accommodations for the June 2, 2026 meeting.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10310 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting
The National Institute on Deafness and Other Communication Disorders is holding a private virtual meeting on July 20, 2026, to review grant applications. This meeting affects researchers seeking funding for projects related to hearing and communication disorders. No public access is allowed to protect sensitive information, and the decisions could impact future research funding.
2026-10231 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings on June 25, 2026, to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding which science projects get funding. Researchers applying for grants should note the date, as these reviews impact who gets money for their work.
2026-10175 — Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a private virtual meeting on June 9, 2026, to review grant applications about infectious diseases and immunology. This closed session protects sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as this review impacts funding decisions.
2026-09947 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for exciting health science projects. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-10022 — Submission for OMB Review; 30-Day Comment Request; Early Career Reviewer Program Online Application and Vetting System (Center for Scientific Review)
The NIH wants your thoughts on their Early Career Reviewer Program’s new online application and review system. This affects early career scientists applying to review research, making the process smoother and digital. You’ve got 30 days to share your feedback—no cost changes, just a smarter way to apply!
2026-10021 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and evaluate grant applications related to health and cancer research. These meetings are private to protect sensitive information and personal privacy. Researchers applying for grants and NIH staff are the main players, with no direct cost changes announced but important deadlines to keep in mind.
Previous / Next Documents
Previous: 2026-01942 — Eunice Kennedy Shriver National Institute of Child Health and Human Development; Amended Notice of Meeting
Heads up! The Eunice Kennedy Shriver National Institute of Child Health and Human Development is extending its big May 2026 meeting from one day to two days. This change affects anyone interested in medical rehab research and means more time for important discussions, all happening in Bethesda and open to the public.
Next: 2026-01944 — Importer of Controlled Substances Application: Sharp Clinical Services, LLC
Sharp Clinical Services, LLC wants to become an official importer of certain controlled substances, including some Schedule I drugs like Gamma Hydroxybutyric Acid and MDMA. This affects companies involved in drug manufacturing and regulation, who can comment or request a hearing by March 4, 2026. No fees or immediate changes yet, but this step could impact drug supply chains soon.